Nelly Conus

A staggering 72% of clinical trials fail to meet enrolment goals, often due to inconvenient trial logistics for patients. Direct-to-patient (DTP) clinical trial supply offers a promising solution, bringing medications and trial materials directly to patients' but challenges remain.

This interactive workshop explores how AI can be harnessed to overcome these hurdles and empower a smoother, more patient-centred DTP experience.

Core Focus Areas:

• Defining the Landscape: We'll establish a clear understanding of AI and its role in DTP supply chains, ensuring everyone is on the same page.
• Conquering Challenges: Explore how AI can tackle common roadblocks, including improving supply chain visibility, navigating regulatory complexities, and determining the best model – fully DTP or a hybrid approach.
• Temperature Control with Precision: Discover AI-powered solutions for maintaining optimal temperature control throughout the DTP journey, safeguarding the integrity of sensitive medications.
• Empowering Health Equity: Learn how AI can be leveraged to remove barriers and ensure diverse patient populations have equitable access to DTP clinical trials.

FINDING NOVEL APPROACHES TO CORE CHALLENGES: BENCHMARKING SUCCESS IN OVERCOMING KEY OPERATION & STRATEGIC BARRIERS

How does it work? Choose a 45-minute discussion on a pressing clinical trial supply topic. Interact with your peers, identifying contemporary challenges and novel approaches to confronting them. Each roundtable is led by a subject matter expert.

Following the conclusion of the discussions, there will be a 30-minute feedback session, where the roundtable leaders will share the key findings that came out of their respective discussions.

The discussion groups are:

GROUP A - HOW CAN WE ADAPT SUCCESSFULLY TO THE PACE OF TECHNOLOGICAL CHANGE?

Ana-Zeralda Canal-Hamann, Senior Clinical Trial Supplies Manager, DebioPharm

GROUP B - ARE WE TRULY DOING PATIENT-CENTRICITY – AND OF YES, HOW ARE YOU DOING IT?

GROUP C - HOW CAN WE CONTAIN COST WITHOUT COMPROMISING PATIENT SUPPLY RISK?

Cinthia Travaglini, Head of Global Development - Supply Lead & Study Set Up, UCB

GROUP D - HOW CAN WE GO FURTHER IN REDUCING WASTE ACROSS THE SUPPLY CHAIN

GROUP E - HOW TO MITIGATE THE ENVIRONMENTAL IMPACT OF DIRECT-TO-PATIENT?

Costanza Carmi, Clinical Supply Lead, Chiesi

GROUP F - HOW CAN WE ENSURE WE HAVE ACCURATE & UP-TO-DATE REGULATORY INTELLIGENCE?